Scan any vial to its lab reportFree shipping over $200Every lot tested by an independent labShips within one business day
GLP3-RT Peptide · RUO
Peptide

GLP3-RT

$64.99
  • Independent labTested per lot
  • Coded labelOpens the lot report
  • Fast dispatchShips in one business day

For in-vitro laboratory research only. Not for human or veterinary use.

Lot results

Per certificate
Form
Lyophilized powder
Storage
−20 °C, away from light

GLP3-RT is a synthetic 39-amino-acid peptide. It is an investigational compound that acts on three receptors: GIP, GLP-1 and glucagon. It has not been approved as a medicine.

  • Type: Synthetic 39-amino-acid peptide
  • Molecular weight: about 4731 Da
  • Size: Available in 10 mg and 20 mg vials.

Supplied as a lyophilized (freeze-dried) powder in a sealed glass vial. Store sealed at −20 °C, away from light and moisture.

Identity, purity and fill results for the lot you receive are on its certificate of analysis.

For in-vitro laboratory research only. Not for human or veterinary use.

 

◆Compound profile

What is in the vial

Chain length
39 amino acids
Molecular weight
≈ 4731 Da
Ends
H · NH2
Sequence · start to end39 residues
HY1AibQGT5FTSDY10SIαMeLLD15KK*AQAib20AFIEY25LLEGG30PSSGA35PPPSNH2
Hydrophobic 14Polar 16Acidic 4Basic 1Modified 4

Aib and αMeL are non-standard amino acids. K* is a lysine carrying a fatty-acid side chain.

Chain length across the catalogamino acids
GHK-Cu
3
KPV
3
Glutathione
3
MT2
7
Semax
7
Selank
7
DSIP
9
MT1
13
MOTS-c
16
Retatrutide
39
Tesamorelin
44
◆Published research

What the literature says

Human trialReviewResearch article
  1. 2022
    Research articleLY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of conceptCoskun T et al. · Cell Metab · PMID 35985340
  2. 2023
    Human trialTriple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 TrialJastreboff AM et al. · N Engl J Med · PMID 37366315
  3. 2023
    Human trialRetatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USARosenstock J et al. · Lancet · PMID 37385280

These are independent, peer-reviewed publications listed for background reading. Ascension Research did not conduct or fund them. They are not claims about this product or about any use in people or animals. For laboratory research only.